Experimental intoxication models are used to study the more common sporadic form of
Parkinson's disease (PD). 1‐Methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyrimidine (MPTP) …

Behavioral analyses of mice intoxicated by the parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3,
6,-tetrahydropyridine (MPTP) have generated conflicting results. We therefore analyzed the …

A degradation of the nigrostriatal dopaminergic (DA-ergic) system is the key component of
pathogenesis of Parkinson's disease (PD). Initial clinical symptoms appear 20–30 years …

The development of animal models of Parkinson's disease is of great importance in order to
test substitutive or neuroprotective strategies for Parkinson's disease. Such models should …

Abstract Systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)
gives rise to motor deficits in humans and other primates which closely resemble those seen …

Parkinson's disease (PD) is a common neurodegenerative disease that appears essentially
as a sporadic condition. It results mainly from the death of dopaminergic neurons in the …

Parkinson's disease is characterized by a severe loss of dopaminergic neurons resulting in
a range of motor deficits. The neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine …

The identification of MPTP, a relatively simple compound which causes selective
degeneration of the substantia nigra after systemic administration, has had an a significant …

Many studies have shown that deficits in olfactory and cognitive functions precede the
classical motor symptoms seen in Parkinson's disease (PD) and that olfactory testing may …

The effects of different dosing paradigms for the administration of 1-methyl-4-phenyl-1, 2, 3,
6-tetrahydropyridine (MPTP) were investigated in C57-black and CF-W albino mice. Several …